| |
|
Click
Here For Low Prices On Vaniqa What Is Vaniqa?Vaniqa is an enzyme inhibitor used topically to slow the growth of unwanted facial hair in women. Vaniqa (eflornithine hydrochloride) Cream, 13.9% demonstrated in clinical trials that it is effective in slowing the growth of unwanted facial hair in up to 60 percent of women. It can take up to 2 months to work.
Vaniqa will not replace current hair removal methods such as tweezing, waxing or shaving. Instead it complements those methods by slowing hair growth. The cream has a unique mechanism of action and is believed to work by blocking an enzyme that is necessary for hair growth. It comes with a patient information leaflet which should be read carefully. Vaniqa DirectionsApply a thin layer of Vaniqa to the affected areas of the face and under the chin, at least 5 minutes after hair removal (e.g., plucking, shaving). Rub in thoroughly. Do not wash the treated area for at least 4 hours. Wait at least 8 hours between applications of this medicine. Cosmetics or sunscreens may be applied after the medicine has dried. Side effects that may go away during treatment include stinging, burning, redness, tingling, rash of the skin or hair bumps (folliculitis). If a dose is missed, skip the missed dose and return to the regular dosing schedule. Do not apply 2 doses at once. Vaniqa is a prescription drug for external use only. On July 31, 2000, Bristol-Myers Squibb Company and The Gillette Company announced that the U.S. Food and Drug Administration (FDA) had approved Vaniqa (eflornithine hydrochloride) Cream, 13.9% as the first topical prescription treatment for women with unwanted facial hair.
Click
Here For Low Prices On Vaniqa For a safe alternative to Vaniqa, suitable for both men and women, click here Adverse Reaction Adverse events reported for most body systems occurred at similar frequencies in Vaniqa and vehicle control groups. The most frequent adverse events related to treatment with Vaniqa were skin-related. Treatment related skin adverse events that occurred in less than 1% of the subjects treated with Vaniqa are: bleeding skin, cheilitis, contact dermatitis, swelling of lips, herpes simplex, numbness and rosacea. Adverse events were primarily mild in intensity and generally resolved without medical treatment or discontinuation of Vaniqa. Only 2% of subjects discontinued studies due to an adverse event related to use of Vaniqa. Overdosage Overdosage information with Vaniqa is unavailable. Given the low percutaneous penetration of this drug, overdosage via the topical route is not expected (see CLINICAL PHARMACOLOGY). However, should very high topical doses (e.g., multiple tubes per day) or oral ingestion be encountered (a 30 g tube contains 4.2 g of eflornithine hydrochloride), the patient should be monitored, and appropriate supportive measures administered as necessary. Storage Store at 25°C (77°F); excursions permitted to 15°C - 30°C (59°F - 86°F) Check the Vaniqa tube crimp and carton end for expiration date and lot number and be sure not to freeze. Other Vaniqa Information pages: |
|
